P2, N=102, Active, not recruiting, Oregon Health and Science University | Trial completion date: Mar 2026 --> Oct 2026

P4, N=148, Recruiting, University of Louisville | Not yet recruiting --> Recruiting

P2, N=138, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed

P=N/A, N=49, Army Medical Center of PLA; Army Medical Center of PLA

Here we provide the basis for further development of trabectedin/irinotecan for patients with ES by the international cooperative groups. ClinicalTrials.gov: NCT04067115 .

P=N/A, N=13, Completed, West Virginia University | Recruiting --> Completed | N=20 --> 13

P2, N=271, Active, not recruiting, Boston University | Recruiting --> Active, not recruiting

P=N/A, N=224, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=16, Recruiting, Italian Sarcoma Group | Trial primary completion date: Dec 2025 --> Dec 2026

Sub-cohorts included patients receiving neoadjuvant therapy (n = 33), primary resection (n = 193), palliative first-line chemotherapy (n = 26), or a palliative salvage therapy with trabectedin (n = 22)...SLFN11 is a prognostic and potentially predictive biomarker in STS in the context of chemotherapy. Our results support a prospective validation, standardization of SLFN11 assessment, and consecutive clinical implementation.

P2, N=100, Recruiting, Italian Sarcoma Group | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=114, Not yet recruiting, Guy's and St Thomas' NHS Foundation Trust | Trial completion date: Jun 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027